Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||2.22%||162.92||0.7%||$1364.82m|
|MRK||Merck & Co., Inc.||0.12%||73.43||0.7%||$1062.62m|
|BMY||Bristol-Myers Squibb Co.||0.92%||56.84||1.0%||$817.37m|
|LLY||Eli Lilly & Co.||0.30%||246.31||1.1%||$708.15m|
|DRNA||Dicerna Pharmaceuticals, Inc.||-0.18%||38.18||0.3%||$155.33m|
|RPRX||Royalty Pharma Plc||0.64%||37.89||0.1%||$117.35m|
|NVO||Novo Nordisk A/S||0.63%||107.75||0.1%||$82.81m|
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.